Patent ID: 7311913
Filing Date: 2007-12-25
Classification: A61K,A61P,C07K

Abstract:
1. A method of treating a patient having or at risk of a thrombotic disease or atherosclerosis, comprising: administering to said patient an effective dose of a humanized immunoglobulin, wherein said humanized immunoglobulin binds to the von Willebrand factor and inhibits the binding of the von Willebrand factor to the GPIb protein and said humanized immunoglobulin comprises (a) complementarity determining regions comprising amino acid sequences RFWMS, residues 49-53 of SEQ ID NO: 6, EVNPDNNTMNYTPSLKD, residues 68-84 of SEQ ID NO: 6, and PPYYGSYGGFAY, residues 117-128 of SEQ ID NO: 6, in the heavy chain (HC), and RASENIYNNLA, residues 44-54 of SEQ ID NO: 8, AATNLAD, residues 70-76 of SEQ ID NO: 8 and GHLWTSPYT, residues 109-117 of SEQ ID NO: 8, in the light chain (LC), and (b) framework regions of human antibody, wherein the framework regions of a human antibody correspond to residues 21-43, 55-69, 77-108, and 118-127 of SEQ ID NO: 8 for the light and to residues 19-48, 54-67, 85-116, and 119-139 of SEQ ID NO: 6 for the heavy chain, and wherein at least one amino acid selected from the group consisting of LC-48, residue 68 of SEQ ID NO: 8, LC-70, residue 90 of SEQ ID NO: 8, LC-71, residue 91 of SEQ ID NO: 8, HC-28, residue 46 of SEQ ID NO: 6, HC-48, residue 66 of SEQ ID NO: 6, HC-49, residue 67 of SEQ ID NO: 6, and HC-67, residue 85 of SEQ ID NO: 6, is replaced with an amino acid present in the equivalent position of a mouse AJvW-2 antibody heavy or light chain variable region framework.